Join now & save up to 80% on medication

JOIN NOW
Select Language:

Join now and save 80% on medication

Register/Login

What are Biosimilar Drugs?

Share Post:

What are biosimilar drugs?

In its simplest definition, biosimilar drugs are synthetic versions of biologic drugs that have been utilized to treat various illnesses and conditions. These are medicines that are very close to biologic drugs in terms of their function and structure.

In order to understand biosimilars, it is essential to know about biologics first. Biologics consists of proteins made by living organisms. It is entirely different from traditional drugs, where chemicals are used and are referred to as small molecules contained in pills like aspirin.

As mentioned, biosimilars act as a replica of biologic drugs. Each of the produced biosimilars is made with the same materials and similar processes as its reference medicines. These reference medicines are biologic drugs that have been used for many years now. The best examples of biologic drugs are Infliximab (Remicade), Etanercept (Enbrel), and Adalimumab (Humira).

Biosimilars vs Generics

The main differences between biosimilars and generics involve their molecular sizes, structures, complexity, and costs of their development. Consider the following information:

Biosimilar drugs, alongside their reference biologic medicines, are very much the same but not entirely identical. This is because of the following reasons:

  • Biologic drugs are large and complex.
  • Biologic drugs consist of living organisms instead of chemicals.

On the other hand, generic drugs have identical properties to their reference medicines. Unlike biosimilars, generics are made of small molecules that are produced with chemical ingredients and processes. Generic drugs are the exact copies of what we call branded medications.

FDA-approved biosimilars

The following are biosimilar drugs approved by the Food and Drug Administration. The table below includes their reference products and approval date.

  Biosimilar Drugs  Reference Products (Medicines)  Approval Dates
Byooviz (ranibizumab-nuna)Lucentis (ranibizumab)September 2021 
Rezvoglar (insulin glargine-aglr)Lantus (insulin glargine)December 2021
Yusimry (adalimumab-aqvh)Humira (adalimumab)December 2021
Releuko (filgrastim-ayow)Neupogen (filgrastim)February 2022
Alymsys (bevacizumab-maly)Avastin (bevacizumab)April 2022
Fylnetra (pegfilgrastim-pbbk)Neulasta (pegfilgrastim)May 2022
Cimerli (ranibizumab-eqrn)Lucentis (ranibizumab) August 2022
Stimufend (pegfilgrastim-fpgk)Neulasta (pegfilgrastim)September 2022
Vegzelma (bevacizumab-adcd)Avastin (bevacizumab)September 2022
Profile image of CDI Staff Writer

Written by CDI Staff WriterOur internal team are experts in many subjects. on November 21, 2022

Related Products

Related Articles

Diabetes, General Health,
Best Practices for Navigating U.S. Prescription Policies

The landscape of U.S. prescription policies can be overwhelming. With varying regulations from state to state, along with intricate insurance protocols, patients must become familiar with the best practices prescriptions…

Read More
Diabetes, Diabetes Supplies,
Large Scale Real World Evidence Ozempic Actually Reduces Suicide: Debunked Unfounded Concerns

In recent years, Semaglutide has emerged as a groundbreaking medication for managing type 2 diabetes and aiding weight loss in individuals with obesity. Marketed under brand names like Ozempic and…

Read More
Diabetes, Diabetes Supplies,
Best Large Scale Evidence that Ozempic May Reduce All Cause Mortality in Individuals with Chronic Kidney Disease

Discover how semaglutide may reduce the risk of kidney failure and heart complications in individuals with type 2 diabetes and chronic kidney disease.Type 2 diabetes and chronic kidney disease (CKD)…

Read More
Diabetes, Diabetes Supplies,
Worst Cities for Insulin Accessibility in the U.S.

Access to insulin is a critical need for millions of Americans managing diabetes. However, some cities in the United States face significant challenges in providing affordable and consistent insulin access.…

Read More